comparemela.com

Latest Breaking News On - Lipomedix pharmaceuticals - Page 5 : comparemela.com

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08

Rafael Holdings Announces Inducement Grant Under NYSE Rule 303A.08
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

William-conkling
Compensation-committee-of-the-board-directors
Prnewswire-rafael-holdings-inc
York-stock-exchange-rule
Lipomedix-pharmaceuticals-ltd
Rafael-holdings-inc
Barer-institute
Rafael-pharmaceuticals-inc
Company-on
Rafael-holdings
Incentive-plan
New-york-stock-exchange-rule

Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results

Rafael Holdings Reports Second Quarter Fiscal Year 2021 Results News provided by Share this article Share this article NEWARK, N.J., March 17, 2021 /PRNewswire/  Rafael Holdings, Inc., (NYSE: RFL), reported revenue of $1.0 million and a loss per share of $0.50 for the second quarter of its 2021 fiscal year, the three months ended January 31, 2021. Q2 FY 2021 Consolidated Financial and Operational Highlights Revenue of $1.0 million, generated by Rafael Holdings real estate portfolio, decreased from $1.2 million in the year-ago quarter due, in part, to the sale of its building in Piscataway, NJ. Loss per share of $0.50 compared to a loss per share of $0.08 in the year ago quarter primarily due to a $7.0 million impairment of the company s interest in Altira, as described below.

United-states
Israel
Israeli
Howard-jonas
Fordoz-pharma
Joshua-rabinowitz
Third-party
Sarcoma-alliance-for-research
Lipomedix-pharmaceuticals-ltd
Rafael-pharmaceuticals
Princeton-university-office-of-technology-licensing
Rafael-holdings-inc

Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO

Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO Leadership Team Will Build on Pharma Investments News provided by Share this article Share this article NEWARK, N.J., March 11, 2021 /PRNewswire/  Rafael Holdings, Inc., (NYSE: RFL), today announced that its Board of Directors has recruited Ameet Mallik to become the company s Chief Executive Officer, succeeding its founder, Howard Jonas.  Ameet Mallik s appointment will become effective May 1, 2021.  In addition, William Bill Conkling has been named Chief Commercial Officer effective March 15, 2021. Ameet Mallik will join Rafael Holdings from Novartis where he is currently Executive Vice President and Head, U.S. Oncology, responsible for Novartis s commercial and medical oncology operations in the United States. 

United-states
Canada
America
Howard-jonas
Rafael-pharma
Lipomedix-pharmaceuticals-ltd
Fordham-university
Rafael-holdings-inc
Novartis
Barer-institute
Rafael-pharmaceuticals-inc
York-university-stern-school-of-business

Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO

Rafael Holdings Enhances Senior Management Team with Additions of Ameet Mallik, CEO and William Conkling, CCO
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United-states
Canada
America
Howard-jonas
Rafael-pharma
Lipomedix-pharmaceuticals-ltd
Fordham-university
Rafael-holdings-inc
Novartis
Barer-institute
Rafael-pharmaceuticals-inc
York-university-stern-school-of-business
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.